Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma

被引：4
|
作者：
Zhou, Ying [1 ]
Xu, Xiaohong [1 ]
机构：
[1] Nantong Univ, Dept Oncol, Affiliated Tumor Hosp, Nantong, Peoples R China
来源：
HEMATOLOGY | 2022年 / 27卷 / 01期
关键词：
PCNSL; relapsed and refractory; BTK inhibitors; PI3; K; mTOR inhibitors; immunomodulators; immune checkpoint inhibitors; PRIMARY CNS LYMPHOMA; PHASE-II; LENALIDOMIDE MONOTHERAPY; IBRUTINIB MONOTHERAPY; CELL; TEMSIROLIMUS; COMBINATION; NIVOLUMAB; BLOCKADE;
D O I：
10.1080/16078454.2021.2019363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL.
引用
收藏
页码：105 / 112
页数：8
相关论文
共 50 条
  • [1] New hopes in relapsed refractory primary central nervous system lymphoma
    Calimeri, Teresa
    Steidl, Carolina
    Fiore, Paolo
    Ferreri, Andres J. M.
    [J]. CURRENT OPINION IN ONCOLOGY, 2023, 35 (05) : 364 - 372
  • [2] Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
    Raizer, Jeffrey J.
    Rademaker, Alfred
    Evens, Andrew M.
    Rice, Laurie
    Schwartz, Margaret
    Chandler, James P.
    Getch, Christopher C.
    Tellez, Claudia
    Grimm, Sean A.
    [J]. CANCER, 2012, 118 (15) : 3743 - 3748
  • [3] Management of refractory or relapsed primary central nervous system lymphoma (Review)
    Yamanaka, Ryuya
    [J]. MOLECULAR MEDICINE REPORTS, 2009, 2 (06) : 879 - 885
  • [4] Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
    Batchelor, T. T.
    Lesser, G. J.
    Grossman, S. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] SALVAGE CHEMOTHERAPY WITH TEMOZOLOMIDE IN REFRACTORY OR RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Makino, Keishi
    Nakamura, Hideo
    Hide, Takuichiro
    Kuratsu, Jun-ichi
    [J]. NEURO-ONCOLOGY, 2009, 11 (06) : 916 - 916
  • [6] Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma
    Voloschin, Alfredo D.
    Betensky, Rebecca
    Wen, Patrick Y.
    Hochberg, Fred
    Batchelor, Tracy
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (02) : 211 - 215
  • [7] Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma
    Alfredo D. Voloschin
    Rebecca Betensky
    Patrick Y. Wen
    Fred Hochberg
    Tracy Batchelor
    [J]. Journal of Neuro-Oncology, 2008, 86 : 211 - 215
  • [8] Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan
    Fischer, L
    Thiel, E
    Klasen, HA
    Kirchen, H
    Jahnke, K
    Korfel, A
    [J]. NEUROLOGY, 2004, 62 (10) : 1885 - 1887
  • [9] Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma
    Lin, Zhiguang
    Ma, Jingjing
    Ma, Yan
    Li, Qing
    Kang, Hui
    Zhang, Mengxue
    Chen, Bobin
    [J]. ACTA HAEMATOLOGICA, 2024,
  • [10] Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: Final report
    Voloschin, AD
    Wen, P
    Hochberg, F
    Batchelor, T
    [J]. NEUROLOGY, 2004, 62 (07) : A478 - A478
12345